Biotech raises $820M to bring China-sourced immunology drug to market via reverse merger
read at Endpoints ↗DealPositive
A biotech company has secured $820 million in investor commitments this month to bring its immunology drug, developed in China, to public markets.
The funding will be used to complete a reverse merger, a strategy that has become increasingly popular among biotech firms seeking faster access to capital and a public listing.
Industry observers view this as part of a broader resurgence of reverse mergers in the sector, highlighting continued investor appetite for innovative immunology assets.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Biotech's reverse merger renaissance poised to continue”
read at Endpoints ↗74 words · retrieved Aug 17
comments(0)
5-min edit window · permanent after that